Literature DB >> 17031656

Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.

Mingqi Qu1, Tommie Olofsson, Sunna Sigurdardottir, Chao You, Hannu Kalimo, Monica Nistér, Anja Smits, Zhi-Ping Ren.   

Abstract

Oligoastrocytomas are glial tumours consisting of a mixture of neoplastic astrocytic and oligodendroglial cells. Genetic alterations of oligoastrocytomas include loss of heterozygosity of chromosomes 1p and/or 19q (LOH 1p/19q), typically occurring in oligodendrogliomas, and mutations of TP53, frequently occurring in astrocytomas. To investigate whether these neoplastic cell types in oligoastrocytomas have different genetic profiles, we examined the two different components of oligoastrocytomas in comparison with the histological diagnosis of the specific tumour area for LOH 1p/19q and TP53 mutations by using microdissection technique. We found a variety of lost markers for 1p and 19q, and the presence of two different TP53 mutations in the tumour samples. In the majority of cases (9/11), the oligodendroglial and astrocytic components of an individual oligoastrocytoma displayed the same genotype. We present two cases of biphasic oligoastrocytomas with aberrant findings, suggesting the coexistence of genetically and morphologically distinct tumour cell clones in these tumours. In one case, the oligodendroglial part of the tumour showed LOH19q, whereas the astrocytic part showed TP53 mutation (codon 273). In another case, we found LOH 1p/19q in the oligodendroglial component, but two retained areas on chromosome 1p in the astrocytic component of the tumour. No evidence was found for the coexistence of tumour cells with the two genotypical changes within the same morphological region of one individual tumour. The two cases of biphasic oligoastrocytomas in our sample that display a different genotype in the astrocytic and oligodendroglial part of the tumour show that different components of an oligoastrocytoma may be derived from different cell clones during neoplastic transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031656     DOI: 10.1007/s00401-006-0142-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  19 in total

1.  Intratumoral patterns of clonal evolution in gliomas.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Inês Crespo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Maria Celeste Lopes; Alberto Orfao
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

2.  Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate?

Authors:  Yingjie Zou; Harrison Xiao Bai; Yi Shu; Chao Mao; Bin Yan; Li Yang
Journal:  J Neurooncol       Date:  2015-01-03       Impact factor: 4.130

3.  Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.

Authors:  Cinthya J Zepeda-Mendoza; Rachael A Vaubel; Shabnam Zarei; Cristiane M Ida; Martin Matthews; Sara Acree; Aditya Raghunathan; Caterina Giannini; Robert B Jenkins
Journal:  Acta Neuropathol       Date:  2020-03-13       Impact factor: 17.088

4.  The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Authors:  J Bryan Iorgulescu; Matthew Torre; Maya Harary; Timothy R Smith; Ayal A Aizer; David A Reardon; Jill S Barnholtz-Sloan; Arie Perry
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

Review 5.  Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.

Authors:  Adriana Olar; Erik P Sulman
Journal:  Semin Radiat Oncol       Date:  2015-02-23       Impact factor: 5.934

6.  Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification.

Authors:  Barbara Klink; Ben Schlingelhof; Martin Klink; Karen Stout-Weider; Stephan Patt; Evelin Schrock
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

7.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Authors:  Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

8.  Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis.

Authors:  Luciana Wernersbach Pinto; Maria Betania Mahler Araújo; Andre L Vettore; Liana Wernersbach; André Campana C Leite; Leila Maria C Chimelli; Fernando Augusto Soares
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

9.  Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals.

Authors:  Yan-Xi Li; Abudumijiti Aibaidula; Zhifeng Shi; Hong Chen; Kay Ka-Wai Li; Nellie Yuk-Fei Chung; Ryan Rui Yang; Danny Tat-Ming Chan; Wai Sang Poon; Ka Lok Ryan Lee; Ying Mao; Jinsong Wu; Aden Ka-Yin Chan; Liangfu Zhou; Ho-Keung Ng
Journal:  J Neurooncol       Date:  2018-05-14       Impact factor: 4.130

Review 10.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.